306 related articles for article (PubMed ID: 30357491)
1. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.
Umezu D; Okada N; Sakoda Y; Adachi K; Ojima T; Yamaue H; Eto M; Tamada K
Cancer Immunol Immunother; 2019 Feb; 68(2):201-211. PubMed ID: 30357491
[TBL] [Abstract][Full Text] [Related]
2. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
[TBL] [Abstract][Full Text] [Related]
3. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
4. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.
Fu Y; Liu CJ; Kobayashi DK; Johanns TM; Bowman-Kirigin JA; Schaettler MO; Mao DD; Bender D; Kelley DG; Uppaluri R; Bi WL; Dunn IF; Tao Y; Luo J; Kim AH; Dunn GP
Sci Rep; 2020 Jun; 10(1):9027. PubMed ID: 32493985
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PI3Kδ Differentially Regulates Poly I:C- and Human Metapneumovirus-Induced PD-L1 and PD-L2 Expression in Human Bronchial Epithelial Cells.
Ogawa T; Kan-O K; Shiota A; Fujita A; Ishii Y; Fukuyama S; Matsumoto K
Front Immunol; 2021; 12():767666. PubMed ID: 34899719
[TBL] [Abstract][Full Text] [Related]
6. Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells.
Zhang X; Cheng C; Hou J; Qi X; Wang X; Han P; Yang X
Cell Mol Immunol; 2019 Apr; 16(4):392-400. PubMed ID: 29568117
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
8. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Taube JM; Klein A; Brahmer JR; Xu H; Pan X; Kim JH; Chen L; Pardoll DM; Topalian SL; Anders RA
Clin Cancer Res; 2014 Oct; 20(19):5064-74. PubMed ID: 24714771
[TBL] [Abstract][Full Text] [Related]
9. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice.
Dimitrov V; Bouttier M; Boukhaled G; Salehi-Tabar R; Avramescu RG; Memari B; Hasaj B; Lukacs GL; Krawczyk CM; White JH
J Biol Chem; 2017 Dec; 292(50):20657-20668. PubMed ID: 29061851
[TBL] [Abstract][Full Text] [Related]
10. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
[TBL] [Abstract][Full Text] [Related]
11. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells.
Noh H; Hu J; Wang X; Xia X; Satelli A; Li S
Cell Commun Signal; 2015 Feb; 13():14. PubMed ID: 25889536
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
15. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Schofield DJ; Percival-Alwyn J; Rytelewski M; Hood J; Rothstein R; Wetzel L; McGlinchey K; Adjei G; Watkins A; Machiesky L; Chen W; Andrews J; Groves M; Morrow M; Stewart RA; Leinster A; Wilkinson RW; Hammond SA; Luheshi N; Dobson C; Oberst M
MAbs; 2021; 13(1):1857100. PubMed ID: 33397194
[TBL] [Abstract][Full Text] [Related]
16. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
[TBL] [Abstract][Full Text] [Related]
17. Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses.
Tanaka R; Ichimura Y; Kubota N; Saito A; Nakamura Y; Ishitsuka Y; Watanabe R; Fujisawa Y; Mizuno S; Takahashi S; Fujimoto M; Okiyama N
J Invest Dermatol; 2022 Jan; 142(1):145-154.e8. PubMed ID: 34310947
[TBL] [Abstract][Full Text] [Related]
18. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.
Schonfeld M; Zhao J; Komatz A; Weinman SA; Tikhanovich I
J Biol Chem; 2020 May; 295(20):7126-7137. PubMed ID: 32245889
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity.
Karunarathne DS; Horne-Debets JM; Huang JX; Faleiro R; Leow CY; Amante F; Watkins TS; Miles JJ; Dwyer PJ; Stacey KJ; Yarski M; Poh CM; Lee JS; Cooper MA; Rénia L; Richard D; McCarthy JS; Sharpe AH; Wykes MN
Immunity; 2016 Aug; 45(2):333-45. PubMed ID: 27533014
[TBL] [Abstract][Full Text] [Related]
20. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]